About: http://data.cimple.eu/news-article/15dabc0ea189f42fe4b553c6e7ad5587106c1b65c38b3237add81b17

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/15dabc0ea189f42fe4b553c6e7ad5587106c1b65c38b3237add81b17 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US biotech firm Moderna on Wednesday announced initial data from a small clinical trial that showed its booster shots improved people's immune responses against key coronavirus variants of concern. "We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants," said the company's CEO Stephane Bancel. Forty participants were tested for their levels of neutralizing antibodies six to eight months after their primary vaccination series of two shots. A third shot of either the original Moderna vaccine or a variant-specific booster improved antibody levels against two major variants, which were first detected in South Africa and Brazil. The variant-specific booster performed better than the original shot, producing almost twice as many neutralizing antibodies. The company is also testing a third type of booster, which is a combination of the other two types, and plans to announce results for it soon. Neutralizing antibodies are proteins produced by the immune system that are custom-made to bind to a specific structure of a microbe. In the case of the coronavirus, these are its spike proteins that dot the surface giving it its distinctive crown-like appearance. Binding to these spikes prevents the virus from latching on to and invading our cells. Neutralizing antibodies are therefore important first lines of defense that prevent infection. The immune system does however contain many other key players which, especially among people who were vaccinated against the original virus or previously infected, can kick in and prevent severe disease, even if a variant breaks through and infects the host. ia/bfm
schema:headline	Positive data for Moderna booster against Covid variants
schema:mentions	Clinical trial Antibody Ia (cuneiform) Immune system South Africa Chief executive officer Virus Coronavirus disease Brazil Vaccine Coronavirus Neutralizing antibody Microorganism Radio in New Zealand
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-05 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	83 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software